avelumab 
merck,Pfizer
['oxford bio']
 we pick out patients who are supposed to be tmb non-responders and can identify them as responders. we do this from blood tests, not with tissue. prof. presents compelling data showing benefits of episwitch blood testing in contrast to tumor-based analyses. #esmo22 
Pioneering 3D genomics in health and medicine.